Last updated: May 18, 2026
GLP-1 class side effects
Very common (>10%): Nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, headache, fatigue.
Common (1-10%): Dyspepsia, gastroesophageal reflux, eructation, dizziness, dysgeusia, injection-site reactions, hypoglycemia (when combined with insulin/sulfonylureas).
Uncommon (0.1-1%): Acute pancreatitis, cholelithiasis, cholecystitis, acute kidney injury, hypersensitivity reactions, retinopathy progression (in T2D patients with pre-existing retinopathy).
Rare: Severe gastroparesis, intestinal obstruction, thyroid C-cell tumors (rodent observation).
GHRP class (Ipamorelin, GHRP-2, GHRP-6, Hexarelin)
Common: Mild headache (early cycles), transient flushing post-injection, increased hunger (ghrelin agonism — pronounced for GHRP-6, mild for ipamorelin).
GHRP-2 specific: Cortisol and prolactin elevation (10-20% above baseline).
GHRP-6 specific: Strong appetite stimulation.
Hexarelin specific: Reported receptor desensitization with chronic use.
Ipamorelin: Cleanest profile — minimal cortisol/prolactin change, no significant appetite increase.
GHRH class (Sermorelin, Tesamorelin, CJC-1295)
Common: Injection-site redness, flushing, mild headache.
With chronic high dosing: Joint discomfort, water retention, paresthesias (CTS-like), decreased insulin sensitivity (monitor fasting insulin and HbA1c).
Tesamorelin specific: Glucose elevation in some patients, mild peripheral edema.
Tissue repair peptides (BPC-157, TB-500)
Across rodent literature and limited human reports, both peptides have been notably well tolerated. Reported effects:
- Injection-site reactions (typically mild)
- Transient headache (occasional)
- Mild GI changes (rare)
Theoretical concerns about any tissue-stimulating peptide potentially promoting growth of latent tumors are not observed in published animal studies but remain unstudied in long-term human cohorts.
Longevity peptides (Epitalon, MOTS-c, Thymalin)
Sparse human data. Russian research group reports describe favorable tolerability. No specific dose-limiting toxicities reported. Theoretical considerations include telomerase activation (epitalon) and cellular metabolism shifts (MOTS-c) that may have unknown long-term effects.
Cognitive peptides (Selank, Semax, Dihexa)
Selank, Semax (intranasal): Generally mild — nasal irritation, transient headache, occasional fatigue.
Dihexa (oral or injectable): Limited human data; theoretical concerns about angiotensin-pathway effects.
Cosmetic peptides (GHK-Cu, Matrixyl, Argireline)
Topical use: minimal systemic absorption, very well tolerated.
GHK-Cu (injectable for hair/wound healing): Mild injection-site reactions, occasional metallic taste (rare).
Melanotan I and II
Melanotan I (afamelanotide, FDA-approved for erythropoietic protoporphyria): Generally well-tolerated; can cause hyperpigmentation of moles and freckles.
Melanotan II (not FDA-approved): Nausea, flushing, increased libido, spontaneous erection, darkened moles/freckles, increased skin pigmentation, occasional priapism.
Khavinson bioregulators
Reported very well-tolerated in Russian research. Tissue-specific peptide bioregulators are dosed at very low microgram quantities and produce minimal systemic effects.
Serious adverse events: when to seek emergency care
- Severe abdominal pain radiating to back (suspect pancreatitis)
- Persistent vomiting with dehydration
- Sudden severe headache, vision changes
- Chest pain, shortness of breath
- Severe allergic reaction (face/throat swelling, severe rash)
- Unusual bleeding or bruising
How long do side effects last?<br />
GLP-1 GI symptoms typically peak during dose escalation and improve over 4-8 weeks at each dose level. GH-class side effects (water retention, joint discomfort) often resolve when cycling off.
Can side effects be reduced?<br />
Slower titration (especially for GLP-1 class), proper hydration, eating smaller meals, and starting at lower doses than recommended can all reduce GI side effects.
When do thyroid cancer warnings actually apply?<br />
The medullary thyroid carcinoma (MTC) warning for GLP-1 drugs is based on rodent studies at supratherapeutic doses. Human data has not demonstrated increased MTC risk, but contraindication remains for individuals with personal or family history of MTC or MEN2 syndrome.
Are there any peptides without side effects?<br />
Every active compound has potential side effects. Some peptides (Ipamorelin, GHK-Cu topical) have particularly clean profiles in studied populations.